Do analysts rate ACB or TENX?

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 648.66%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tenax Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40

Is IKT or TENX more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Tenax Therapeutics N/A -61.54% -57.42%

Tenax Therapeutics (TENX) Competitors

$1.87 +0.01 (+0.54%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.87 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Compare

TENX vs. ACB, BIOA, IKT, VNDA, and EYPT

Should you buy Tenax Therapeutics stock or one of its competitors? Tenax Therapeutics's main competitors and comparable companies include Aurora Cannabis (ACB), BioAge Labs (BIOA), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), and Eyepoint Pharmaceuticals (EYPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tenax Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Aurora Cannabis has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Tenax Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.19	-$88.13M	-$1.41	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aurora Cannabis had 25 more articles in the media than Tenax Therapeutics. MarketBeat recorded 26 mentions for Aurora Cannabis and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.82 beat Aurora Cannabis' score of 0.27 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Tenax Therapeutics	Very Positive

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 648.66%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Tenax Therapeutics beats Aurora Cannabis on 10 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

BioAge Labs currently has a consensus target price of $36.57, indicating a potential upside of 476.84%. Tenax Therapeutics has a consensus target price of $14.00, indicating a potential upside of 648.66%. Given Tenax Therapeutics' higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

1.7% of Tenax Therapeutics shares are held by institutional investors. 17.6% of BioAge Labs shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioAge Labs had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for BioAge Labs and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.82 beat BioAge Labs' score of 0.93 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAge Labs	Positive
Tenax Therapeutics	Very Positive

Tenax Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Tenax Therapeutics	N/A	-61.54%	-57.42%

BioAge Labs has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Tenax Therapeutics has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	32.37	-$80.61M	-$2.38	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Summary

BioAge Labs and Tenax Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Inhibikase Therapeutics has higher revenue and earnings than Tenax Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,057.28	-$48.26M	-$0.43	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Inhibikase Therapeutics' return on equity of -42.80% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Inhibikase Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Inhibikase Therapeutics currently has a consensus target price of $5.40, indicating a potential upside of 174.11%. Tenax Therapeutics has a consensus target price of $14.00, indicating a potential upside of 648.66%. Given Tenax Therapeutics' higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.82 beat Inhibikase Therapeutics' score of 0.76 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Positive
Tenax Therapeutics	Very Positive

Summary

Inhibikase Therapeutics beats Tenax Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Vanda Pharmaceuticals?

Tenax Therapeutics (NASDAQ:TENX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Tenax Therapeutics has higher earnings, but lower revenue than Vanda Pharmaceuticals. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Vanda Pharmaceuticals	$216.10M	1.28	-$220.47M	-$4.63	N/A

Tenax Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Tenax Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 648.66%. Vanda Pharmaceuticals has a consensus price target of $13.08, indicating a potential upside of 186.29%. Given Tenax Therapeutics' higher possible upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40
Vanda Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Tenax Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than Tenax Therapeutics. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.82 beat Vanda Pharmaceuticals' score of 0.56 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenax Therapeutics	Very Positive
Vanda Pharmaceuticals	Positive

Summary

Tenax Therapeutics and Vanda Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Eyepoint Pharmaceuticals and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.82 beat Eyepoint Pharmaceuticals' score of 0.36 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
Tenax Therapeutics	Very Positive

Tenax Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	9.34	-$231.96M	-$3.74	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tenax Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Tenax Therapeutics' return on equity of -61.54% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Eyepoint Pharmaceuticals currently has a consensus target price of $25.70, suggesting a potential upside of 655.88%. Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 648.66%. Given Eyepoint Pharmaceuticals' higher possible upside, research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Tenax Therapeutics beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.98M	$12.40B	$7.25B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-1.26	797.58	275.29	26.14
Price / Sales	N/A	751.21	582.85	87.88
Price / Cash	N/A	86.66	76.96	53.71
Price / Book	0.18	10.71	11.22	6.33
Net Income	-$52.60M	$2.84B	$3.50B	$382.15M
7 Day Performance	-5.56%	-0.94%	-0.89%	-1.40%
1 Month Performance	0.54%	-3.67%	-4.02%	-3.35%
1 Year Performance	-74.93%	-3.97%	7.13%	1.49%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	4.0381 of 5 stars	$1.87 +0.5%	$14.00 +648.7%	-74.9%	$69.98M	N/A	N/A	16	Positive News
ACB Aurora Cannabis	1.134 of 5 stars	$4.59 +2.9%	N/A	-15.3%	$293.13M	$247.82M	N/A	1,028	Trending News High Trading Volume
BIOA BioAge Labs	3.1015 of 5 stars	$6.29 -1.1%	$36.57 +481.4%	+18.5%	$291.90M	$8.99M	N/A	62	News Coverage Analyst Downgrade High Trading Volume
IKT Inhibikase Therapeutics	1.9731 of 5 stars	$1.98 -1.0%	$5.40 +172.7%	+22.4%	$279.07M	$260K	N/A	35
VNDA Vanda Pharmaceuticals	3.7104 of 5 stars	$4.52 -1.3%	$13.08 +189.5%	-13.9%	$276.92M	$215.72M	N/A	533	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. ACB, BIOA, IKT, VNDA, and EYPT

How does Tenax Therapeutics compare to Aurora Cannabis?

Summary

How does Tenax Therapeutics compare to BioAge Labs?

Summary

How does Tenax Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Tenax Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Tenax Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. ACB, BIOA, IKT, VNDA, and EYPT

How does Tenax Therapeutics compare to Aurora Cannabis?

Which has more risk & volatility, ACB or TENX?

Is ACB or TENX more profitable?

Which has higher earnings & valuation, ACB or TENX?

Do insiders & institutionals hold more shares of ACB or TENX?

Does the media refer more to ACB or TENX?

Do analysts rate ACB or TENX?

Summary

How does Tenax Therapeutics compare to BioAge Labs?

Do analysts rate BIOA or TENX?

Do insiders & institutionals have more ownership in BIOA or TENX?

Does the media prefer BIOA or TENX?

Is BIOA or TENX more profitable?

Which has more risk & volatility, BIOA or TENX?

Which has better valuation & earnings, BIOA or TENX?

Summary

How does Tenax Therapeutics compare to Inhibikase Therapeutics?

Which has preferable valuation and earnings, IKT or TENX?

Is IKT or TENX more profitable?

Which has more risk and volatility, IKT or TENX?

Do analysts rate IKT or TENX?

Do institutionals & insiders have more ownership in IKT or TENX?

Does the media prefer IKT or TENX?

Summary

How does Tenax Therapeutics compare to Vanda Pharmaceuticals?

Which has preferable earnings and valuation, TENX or VNDA?

Which has more risk & volatility, TENX or VNDA?

Do analysts prefer TENX or VNDA?

Is TENX or VNDA more profitable?

Do institutionals & insiders believe in TENX or VNDA?

Does the media refer more to TENX or VNDA?

Summary

How does Tenax Therapeutics compare to Eyepoint Pharmaceuticals?

Does the media prefer EYPT or TENX?

Which has better valuation & earnings, EYPT or TENX?

Which has more risk & volatility, EYPT or TENX?

Do institutionals and insiders hold more shares of EYPT or TENX?

Is EYPT or TENX more profitable?

Do analysts recommend EYPT or TENX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools